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ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of liver disease, from steatosis to liver cirrhosis 
in individual who does not consume alcohol in significant amount. The prevalence of NAFLD in Indonesia 
was estimated around 30%, this condition related to the increased incidence of metabolic disorders. Current 
understanding of NAFLD pathogenesis is the third-hit theory, in which insulin resistance resulting in free fatty 
acid accumulation that triggers inflammation causing fibrosis and hepatocyte death, and these conditions are 
not followed by adequate hepatocyte proliferation.
Treatment of NAFLD requires both non-pharmacologic and pharmacologic interventions. Life style 
intervention includes restricting calories, low saturated fat and low sugar diet, and also physical activity. Bariatric 
surgery remains controversial since in several study participants had experienced deterioration of disease. There 
are no definitive treatment for NAFLD currently. Treatment is aimed to improved insulin sensitivity, decreased 
oxidative stress and inflammation. Several agents use for treatment of NAFLD are insulin sensitizer (metformin 
and glitazones), statin, omega-3, vitamin E, ursodeoxycholic acid, orlistat, pentoxyphylline, and losartan. 
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ABSTRAK
Penyakit perlemakan hati non alkoholik (PPHNA) merupakan suatu spektrum penyakit hati dari steatosis 
hingga sirosis hati pada individu yang tidak mengkonsumsi alkohol dalam jumlah yang signifikan. Prevalensi 
PPHNA di Indonesia sekitar 30%, terkait dengan meningkatnya insiden penyakit metabolik. Patogenesis PPHNA 
yang kini berkembang adalah third-hit theory, dimana akibat resistensi insulin didapatkan akumulasi asam 
lemak bebas yang memicu inflamasi sehingga terjadi fibrosis dan kematian hepatosit yang tidak diimbangi 
dengan regenerasi hepatosit.
Pengobatan PPHNA memerlukan intervensi non-farmakologis dan farmakologis. Mulai dari melakukan 
perubahan gaya hidup dengan pembatasan kalori, diet rendah lemak jenuh dan rendah gula, serta aktivitas fisik. 
Pembedahan bariatrik masih menjadi kontroversi dalam tatalaksana pasien PPHNA, karena pada beberapa 
studi didapatkan beberapa subyek yang mengalami perburukan penyakit. Belum ada obat-obatan yang menjadi 
terapi definitif PPHNA, selain dengan melalui perbaikan sensitivitas insulin, menurunkan stres oksidatif dan 
inflamasi. Beberapa pengobatan farmakologis pada PPHNA dapat diberikan insulin sensitizer yaitu metformin 
dan glitazon, statin, omega-3, vitamin E, asam ursodeoksikolat, orlistat, pentoksifilin, dan losartan. 
Kata kunci: PPHNA, pengobatan, farmakologis, non-farmakologis
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INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is 
a spectrum of liver disease, from steatosis until 
cirrhosis in individual who does not consume alcohol 
in significant amount. NAFLD becomes a huge 
health problem in Asia Pacific countries, including 
Indonesia. A literature showed that there was quite high 
incidence of NAFLD in Indonesia, particularly about 
30%.1 High prevelance in various places is associated 
with the increase incidence of metabolic diseases, 
such as diabetes melitus, dyslipidemia, obesity, or 
metabolic syndrome.1 NAFLD is also a risk factor for 
hepatocelullar carcinoma, therefore important to be 
managed.2 For Asia Pacific countries, this burden is 
added with the high incidence of chronic viral hepatitis. 
The association between NAFLD and metabolic 
syndrome is related to insulin resistance.3 In United 
States, it was obtained that 30.1 million individuals 
with obesity suffered from steatosis and 8.6 million 
suffered from steatohepatitis. Obesity becomes a 
separated risk factor for NAFLD, with 5 fold increased 
risk, diabetes melitus either type 1 or 2 becomes a 
dependant risk factor to the occurrence of NAFLD, as 
well as dyslipidemia and viceral adipocytosis, which 
all are part of metabolic syndrome.4
Pathogenesis of NAFLD and non-alcoholic 
steatohepatitis (NASH) alone cannot be explained 
precisely, several current known theories were two-
hits model. The model was introduced by Day et al in 
1998, where insulin resistance played important role in 
causing accumulation of triacylglycerol and free fatty 
acid, which then experienced oxidation and produced 
reactive oxygen species (ROS) and caused the 
occurrence of inflammatory response due to oxidative 
stress.3 Till date, it still cannot be explained how NASH 
can happen in a person and not to the other person.3,4
Diagnosis of NAFLD is still a challenge for 
practitioner. Till current, liver biopsy is a gold 
standard for the establishment of diagnosis. Therefore, 
considering that the procedure is quite invasive, it is 
not performed often. In general, suspicion of NAFLD 
is based on the presence of abnormal liver function, 
in individual whose risk has been described above, so 
that NAFLD become the first possibility. However, 
in individual with normal liver function results, the 
possibility of NAFLD cannot be kept aside.5
PATHOGENESIS
Till date, theory which is still developing about 
pathogenesis of NAFLD and NASH is two-hit theory, 
however many factors are believed to play role in the 
occurrence of NAFLD and its progression. Metabolic 
syndrome and insulin resistance is a common condition 
found in NAFLD patients, however not all individual 
with insulin resistance develop NAFLD and vice versa, 
therefore other factors are also predicted to play role in 
the occurrence of NAFLD. Genetic factors associated 
to endogen anti-oxidants and fat distribution are 
suspected to play role in disease progression, where 
some experienced progression to NASH, but not in 
other individuals. Fat accumulation in hepatocytes, 
particularly in the form of triglycerides become the 
absolute requirement to the occurrence of NAFLD, 
however the primary metabolic disorder causing 
this is which involve many factors. Understanding 
NAFLD pathogenesis show that free fatty acid plays 
important role, and triglyceride is suspected to have 
protective role. Free fatty acid induces inflammation 
through nuclear factor-κB (NF-κB) and also causes 
mitochondria dysfunction. Other theory known as 
third-hit theory, is a modification of two-hit theory 
where post inflammation hepatocyte death happens, 
not balanced with regeneration.5,6,7
Figure 1. Pathogenesis of NAFLD based on third-hit theory7
Molecularly, lipid peroxidation happens as a result 
of oxidative stress through mitochondria dysfunction, 
P450 cytochrome activation, and iron overload. 
Oxidative stress causes cell impairment through the 
impairment of organelles, DNA and mtDNA through 
inflammation process mediated by NF-KB activation 
and IKB degradation. Inflammation that happens is 
also mediated by endoplasmic reticulum stress which 
also causes apoptosis, further exacerbated by necrosis, 
oxidative stress, and activation of  NF-KB and other 
mitogenic pathway.8
Insulin play role in regulation of fatty acid 
metabolism, where 25% fatty acid originated from 
lipogenesis which is controlled by sterol regulatory 
element binding protein (SREBP) whose work is 
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mediated by insulin. In NAFLD, there is decrease level 
of double unsaturated fatty acid, particularly γ linolenat 
acid and increase of fatty acid level accompanied with 
decrease ability of fatty acid oxidation. Regulators 
contributing to this event, such as SREBP, peroxisome 
proliferator-activated receptor (PPAR), and farnesyl 
X receptor are mediated by insulin and adipositoxin 
effect.8
DIAGNOSIS
Liver biopsy becomes the gold standard in 
establishment of NAFLD diagnosis, particularly 
in differentiating pure steatosis and steatohepatitis. 
NAFLD is generally suspected in individual with 
transaminase elevation with no apparent reason and 
no history of alcohol consumption. Ultrasonography 
and other radiological modality may give typical 
appearance in NAFLD, however it is often inaccurate 
in determining degree of impairment, therefore biopsy 
still become gold standard.6,9 
Several non-invasive techniques are developed for 
NAFLD evaluation, however there is none which has 
been well validated, including transient elastography, 
tissue inhibitor of metalloproteinase (TIMP)-1, 
hyaluronate acid and procollagen III type III n-peptide 
(PIIINP). Some of these modalities become component 
in non-invasive evaluation in the degree of NAFLD.9
Figure 1. Histopathological appearance showing steatosis 
(A) and fibrosis (B)6 
Table 1. Histopathological criteria in NAFLD6
Grading for steatosis
Grade 1, < 33% of hepatocytes affected 
Grade 2, 33-66% of hepatocytes affected
Grade 3, > 66%  of hepatocytes affected
Grading for steatohepatitis
Grade 1, mild
Steatosis: macrovesicular, involves up to 66% of lobules
Ballooning: occasionally found; zone 3 hepatocytes
Lobular inflammation: scattered and mild acute 
inflammation (polymorphonuclear cells) and occasional 
chronic inflammation (mononuclear cells)
Portal inflammation: none or mild
Grade 2, moderate
Steatosis: any degree; usually mixed macrovesicular 
and microvesicular
Ballooning: obvious and present in zone 3
Lobular inflammation: polymorphonuclear cells may 
be noted in association with ballooned hepatocytes; 
pericellular fibrosis; mild chronic inflammation may be 
seen
Portal inflammation: mild to moderate
Grade 3, severe
Steatosis: involves > 66% lobules (panacinar); 
commonly mixed steatosis
Ballooning: predominantly zone 3; marked
Lobular inflammation: scattered acute and chronic 
inflammation; polymorphonuclear cells may be 
concentrated in zone 3 areas of ballooning and 
perisinusoidal fibrosis
Portal inflammation: mild to moderate
Staging for fibrosis
Stage 1: zona 3 perivenular, perisinusoidal, or pericellular  
              fibrosis; focal or extensive
Stage 2: as above, with focal or extensive periportal fibrosis
Stage 3: bridging fibrosis, focal or extensive
Stage 4: cirrhosis
TREATMENT
In principle, management of NAFLD also 
involves treating the associated comorbidity, such 
as obesity, diabetes, and dyslipidemia.
Non-pharmacological Treatment
• Life style intervention
 Several interventions which are believed to be 
beneficial for NAFLD patients, include aerobic 
exercise with the intensity equal to walking 30 
minutes per day or 5 km per day 3 times a week, 
calorie restriction up to 30 kcal/kg/day with 
lower composition of saturated and trans fatty 
acid, also simple sugar, decrease of 10% body 
weight in 6 months and not so fast because it may 
aggrevate NAFLD. Life style modification is also 
adjusted to the existing comorbidities, particularly 
cardiovascular problem, the most common cause 
of death in NAFLD patients was coronary heart 
disease, where frequently dyslipidemia, obesity, 
and diabetes condition were found, and diabetes 
is a risk factor of cardiovascular disease. NAFLD 
also increases the risk of cardiovascular problem 
through inflammation process.10
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 A study by Bhat et al, in which 60 NAFLD 
patients were involved in India, showed that 
routine physical activity for 30 minutes a day 
with frequency of 5 times a week can decrease 
transaminase level and also improve histological 
appearance in 6 months evaluation.11 Several 
population studies stated that in NAFLD patients, 
there was lower omega-3 consumption, higher 
omega-6 consumption, and also higher amount 
of cholesterol and saturated fatty acid, and less 
consumption of some vitamins, such as: ascorbic 
acid, tocopherol, and fiber. Meanwhile a study 
using 1,000 mg/day and 2,700 mg/day omega-3 in 
NAFLD patients revealed that omega-3 decrease 
ALT, improve the degree of perlemakan in 
ultrasound, and improve histological appearance, 
however the number of samples included were 42 
and 23 patients.12
 Alcohol consumption is known as risk factor 
of liver impairment, however in small amount 
several studies exhibited the opposite effect. The 
American Association for the Study of Liver 
Disease (AASLD) recommend NAFLD patients 
to not consume alcohol in large amount, which is 
4 times per day or 14 times per week for male and 
3 times per day or 7 times per week for female.9
• Bariatric surgery
 Ninety percent patients who undergo bariatric 
surgery will suffer from NAFLD, however 
this procedure is one of the choices in treating 
NAFLD. A study by Mathurin which was cited 
in the guidelines by American Association for the 
Study of Liver Disease (AASLD), showed the 
incidence of NAFLD decrease in obese individuals 
who undergo bariatric surgery, and in individuals 
with NAFLD or NASH, there was histological 
improvement in one or five years after surgery. 
AASLD does not contraindicate bariatric surgery 
in obesity individuals with NAFLD or NASH as 
long as cirrhosis has not happened.9
 Chavez et al, in their publication in Cochrane 
Review concluding from several prospective and 
retrospective cohort, stated that bariatric surgery 
revealed improvement of steatosis and inflammatory 
degree, however some publications reported the 
disease worsening in several individuals, but 
randomized control trial (RCT) on the role bariatric 
surgery was still lacking.13
 Publication by Younossi showed that bariatric 
surgery improve output of cardiovascular risk 
factors, although not specifically stating parameter 
of improvement in liver impairment, improvement 
of diabetes, dyslipidemia decrease the degree of liver 
impairment, also showed NASH improvement in 
82% patients who undergo laparascopic adjustable 
gastric banding.14
Pharmacological Treatment
Several drug groups which can be used in 
NAFLD treatment based on AASLD guidelines and 
several studies reported some drugs commonly used 
were insulin sensitizer, statin, omega-3, vitamin E, 
ursodeoxycolate acid, orlistat, pentoksifilin, losartan.9,15
• Metformin
 Metformin is a drug from the insulin sensitizer 
group, where this drug can be used because insulin 
resistance is known to have role in the pathogenesis 
of NAFLD. Several studies showed that metformin 
improve insulin resistance in NAFLD patients and 
also improve transaminase. Some studies which use 
metformin include treatment of NAFLD in children 
(TONIC) study, this study compare metformin 
and vitamin E, both decrease aminotransferase 
level, however vitamin E is better in improving 
histopathological appearance in NASH. Other 
studies by Larine et al and Bugianessi et al, in year 
2005 revealed that metformin 2 g/day improve 
aminotransferase better compared to vitamin E.16,17
 Garinis et al conducted RCT in 50 NAFLD patients 
comparing metformin and hypocaloric (decrease 500 
kcal per day) and hypocaloric diet only, obtained 
improvement in ultrasound results in the group which 
received metformin (p < 0.0001).18 Haukeland et al 
compared administration of metformin and placebo 
in 48 patients and obtained insignificant result in 
histological appearance of those patients.19
 Other studies by Nadeau et al comparing metformin 
and placebo in 55 NAFLD patients, there was no 
significant difference through ultrasound.20 Study 
by Shields et al comparing 19 NAFLD patients 
receiving metformin 500 mg uptitrated to 1,000 mg 
with diet and exercise or diet and exercise alone, 
showed improvement in histological appearance.21
• Glitazone
 Glitazone, is an insulin sensitizer working in 
skeletal muscle and liver, increasing glucose 
uptake by improving peripheral insulin resistance. 
First drug from this group is troglitazone, however 
there is no study which use this drug. Troglitazone 
has higher hepatotoxic side effect compared to the 
following two drugs, particularly rosiglitazone dan 
pioglitazone.22
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy178
Perdana Aditya, C Rinaldi A Lesmana
 Aithal et al performed an RCT in 74 non-DM 
patients who have been proven to suffer from 
NASH through histology and ultrasound, patients 
received pioglitazone 30 mg and plasebo, results 
showed pioglitazone improve hepatocelullar 
impairment, but not for other parameter.23 Belfort 
et al in 2006 compare pioglitazone 30 mg uptitrated 
up to 45 mg with placebo, both groups received low 
calorie diet, through histology there was significant 
improvement in steatosis, necroinflammation and 
fibrosis in group receiving pioglitazone.24
 Sanyal et al conducted two studies; initial study in 
2004 compared pioglitazone 30 mg and vitamin 
E 400 IU, concluded that there was inflammation 
improvement in both groups. The following study 
in 2010, Sanyal performed RCT to 247 patients 
comparing vitamin E, pioglitazone and placebo, 
observation was conducted for 96 weeks, resulted 
in histological improvement in vitamin E and 
pioglitazone groups.25,26
 Other group of glitazone, which is rosiglitazone is 
said to improve degree of NAFLD better compared 
to metformin, however both combination has 
better effects compared to single administration.27 
In histological evaluation, rosiglitazone inhibit 
hepatocytes ballooning, portal inflammation and 
fibrosis overall compared to placebo.28
• Omega-3
 Omega-3 improve lipid metabolism in liver, 
as regulator of transcription factors such as 
peroxisome-poliferator-activated receptor (PPAR), 
sterol receptor element binding protein (SREBP-1), 
and carbohydrate responsive element building 
(ChERBP) which have role in the progression of 
NAFLD to NASH.29
 In their publication in 2012, Di Minno et al 
reviewed 7 studies on the use of omega-3 in 
NAFLD, from those 7 studies, several performed 
randomization, however the number of subjects 
included in the studies were not big and the 
dose being used varied.30 Those studies showed 
that omega-3 improved transaminase and liver 
profiles, several studies measure homeostatic 
model assessment insulin resistance (HOMA IR) 
and showed improvement.29
 Other meta-analysis and systematic review revealed 
that supplementation of polyunsaturated fatty acid 
(PUFA) gave effect to the biochemistry parameter, 
such as accumulation of liver fat and transaminase, 
however if performing meta-analysis towards 
RCT, there was no significant improvement in 
transaminase. In this review the dose of omega-3 
seemed to give significant difference, however the 
duration of administration was more influential. 
Minimal dose needed to gave effect was > 0.83 
mg/day. Beside improving transaminase, omega-3 
has cardio-metabolic effect which often found 
in NAFLD patients, such as: insulin resistance, 
diabetes, dyslipidemia.31  
• Ursodeoxycholic acid
 Ursodeoxycholic acid (UDCA) has anti-
inflammation, anti-oxidant, and antifibrosis effect 
and can improve liver impairment.32 Studies on 
the administration of conventional and high dose 
ursodeoxycholic acid, most showed transaminase 
and histological improvement. However, one RCT 
with large sample size showed that UDCA did not 
improve the histologic appearance of NAFLD.9 A 
study by Ratziu et al involving 126 subjects with 
NASH which had been proved through biopsy 
and experienced elevation of transaminase, were 
given high dose of UDCA 28-35 mg/kg/day, the 
results were patient experienced improvement of 
transaminase and also decreasing fibrosis marker 
level in the serum.32
• Statin
 NAFLD is closely associated with the presence of 
dyslipidemia, where statin is the most commonly 
used treatment in dyslipidemia through its effect 
inhibiting cholesterol synthesis through HMG-coA-
reduktase inhibition. However, statin is suspected 
to have other effects in NAFLD treatment, 
particularly  anti-inflammatory and anti-fibrosis. 
Statin is known may cause transaminase elevation, 
therefore its use in NAFLD is controversial.33
 Studies on statin administration in NAFLD are 
still limited, statin type, dose, duration, number 
of participating samples, there is no RCT with 
quite big sample size. However, studies which 
use statin, showed satisfying results.34 In 2010, 
Hyogo et al performed a study to 43 dyslipidemia 
patients, who were given atorvastatin 10 mg and in 
the evaluation of biochemistry marker for NASH, 
improvement was reported. This was in line with 
the previous study. This effect is obtained because 
statin has TNF-α inhibition effect.31,35 There is no 
RCT to evaluate the effect of statin administration 
to histopathological appearance, the use of statin 
alone becomes controversial because in several 
patients, there was elevation of transaminase level, 
however the incidence of severe liver dysfunction 
was very rare. Some publications and also AASLD 
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in its guidelines in 2012 stated that statin was safe 
to be used in patients with liver dysfunction and 
in patients with chronic liver disease (including 
NAFLD and NASH) the increase risk of drug 
induced liver disease (DILI) was not proven.9,36 
• Vitamin E
 AASLD guidelines stated that study on vitamin E 
in NASH is still limited, both in the quantity and 
strength of the results. Two large studies on the use 
of vitamin E in NAFLD were pioglitazone, vitamin 
E, or placebo for nonalcoholic steatohepatitis 
(PIVENS) dan treatment of NAFLD in children 
(TONIC). PIVENS compared pioglitazone, vitamin 
E, and plasebo by randomization of 247 adult patients 
with NASH and did not suffer from diabetes mellitus 
(DM). Eighty patients received pioglitazone 30 mg, 
84 received vitamin E 800 IU, and the rest received 
placebo. Both gace significant results if compared 
with placebo in terms of decrease of transaminase 
level, steatosis improvement, however not in fibrosis 
score. While vitamin E is more superior compared 
to pioglitazone in NASH resolution. This study 
also reported that cardiovascular incidence was 
insignificantly different in three groups, where this 
became an issue in the use of high dose vitamin E.9,37
 TONIC study, compared vitamin E 400 IU 
twice daily, metformin 500 mg twice daily, and 
placebo in 175 children aged 8–17 year old. These 
three groups equally experience transaminase 
improvement, however in the group which received 
metformin, decrease of transaminase achieved 
earlier, which is in the first 24 weeks. In terms 
of histologic improvement, vitamin E is better in 
NASH resolution, particularly improve ballooning 
(44%), improve NASH score (41%), but does not 
effect to steatosis, fibrosis and inflammation. While 
metformin only improve ballooning (21%). The 
results of this study is also in line with smaller 
study by Bugianesi et al, as has been discussed 
above where vitamin E improve histologic 
appearance compared to metformin.17
 Other study by Akcam et al in 2011, comparing 
metformin and vitamin E, in this study metformin 
was reported to be better in improving steatosis in 
ultrasound, however this study only involved 67 
patients.38
• Anti-TNF
 The development of second-hit theory where 
inflammation further had role in the progression of 
NAFLD to NASH, resulted in the idea to use anti-
TNF. TNF-α as a pro-inflammatory cytokine plays 
role in stimulating hepatic stellate cells in matrix 
remodelling, further there was suspect in bacteria 
translocation which has role in causing further 
inflammation also support the use of anti-TNF 
in inhibiting progression of  NAFLD. One of the 
drugs which has been tried is pentoksifilin which 
has anti-TNF effect, study showed improvement 
of transaminase level in 12 months and histologic 
improvement in 55% patients, however this study 
only involved 18 patients.39,40
 There has been no study which specifically use 
anti-TNF, such as: entanercept, infliximab or 
adalimumab in NAFLD patients, however a study in 
psoriasis, metabolic syndrome, and NAFLD patients 
using entanercept involving 89 patients, showed 
improvement in transaminase, CRP, fasting insulin 
level, HOMA index in 24 weeks, however in this 
study, NAFLD diagnosis is only established based 
on ultrasound.41 
CONCLUSION
Until now, there is no single drug which can be 
used as definitive therapy in NAFLD. Medications 
which is used based on the pathophysiology include: 
(1) insulin resistance, (2) oxidative stress, and (3) 
inflammation. However, there is no clinical trial with 
quite big sample size which can be used as guideline 
in choosing therapy for NAFLD. Several existing 
studies and with quite big sample size, vitamin E and 
insulin sensitizer group can be used in the management 
of NASH to improve histological appearance. In the 
management of NAFLD or NASH, it need to be noted 
the presence of risk factors, comorbidity, and patients' 
adherence. Managing and controling risk factors are 
important in the management of NAFLD; presence 
of comorbidity can be a consideration in choosing 
treatment in NAFLD.
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